MXCT
MXCT
NASDAQ · Life Sciences Tools & Services

Maxcyte Inc

$1.19
+0.00 (+0.00%)
Financial Highlights (FY 2026)
Revenue
28.86M
Net Income
-38,997,924
Gross Margin
81.2%
Profit Margin
-135.1%
Rev Growth
-9.3%
D/E Ratio
—
Revenue & Net Income
Margin Trends
FY 2026 FY 2025 FY 2024 FY 2023
Gross Margin 81.2% 81.2% 41.4% 41.4%
Operating Margin -157.1% -141.4% 7.9% 8.9%
Profit Margin -135.1% -128.4% 7.9% 6.6%
Income Statement
FY 2026 FY 2025 FY 2024 FY 2023
Revenue 28.86M 31.82M 11.59M 9.98M
Gross Profit 23.42M 25.82M 4.80M 4.13M
Operating Income -45,350,820 -45,000,813 910.9K 885.5K
Net Income -38,997,924 -38,696,947 913.3K 656.0K
Gross Margin 81.2% 81.2% 41.4% 41.4%
Operating Margin -157.1% -141.4% 7.9% 8.9%
Profit Margin -135.1% -128.4% 7.9% 6.6%
Rev Growth -9.3% -9.3% +8.1% +21.4%
Balance Sheet
FY 2026 FY 2025 FY 2024 FY 2023
Total Debt 0 0 17.20M 19.69M
Total Equity — — 38.88M 41.65M
D/E Ratio — — 0.44 0.47
Cash Flow
FY 2026 FY 2025 FY 2024 FY 2023
EBITDA -41,657,931 -43,632,893 1.25M 1.22M
Free Cash Flow — — 402.0K 324.3K